We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type of risk assessment test for prospective mothers prior to (but not during) pregnancy, and for mothers during the early postnatal period. Our goal is to provide families with options to materially reduce the occurrence or severity of MARA. Our precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to MARA, thereby enabling the earliest risk assessment for the development of autism in a child.

Health Care

Life Sciences

MARAbio

Judy Van De Water

Michael S. Paul

The Leadership Team at MARAbio drives the company's strategic vision and operational oversight, ensuring alignment with its mission to mitigate the risk of Maternal Autoantibody Related Autism. Comprising the CEO, Chief Medical Advisor, and Founder, this dynamic group fosters innovation in product development, oversees clinical research initiatives, and cultivates key partnerships to enhance awareness and accessibility of MARA risk assessment testing.

Leadership Team

About

Team members

Other teams at MARAbio

Clinical and Research Development